title: Making personalized prostate cancer medicine a reality: challenges and opportunities in the re-establishment of gold standards.
abstract: Prostate cancer is a serious multidimensional disorder that arises because of misrepresentation of signaling cascades and acquired resistance against apoptosis. It is progressively becoming more insurmountable because of rheostat like switching of oncogenic signaling in androgen dependent and androgen depleted microenvironment. Additionally, oncogenic fusion proteins have been explored in prostate cancer tissues thus adding another layer of complexity to the targeting of protein network in cancer cell and generate hurdles in the standardization of therapy. In this Review we briefly describe identified oncogenic fusion transcripts in prostate cancer and suggest utilization of this biomarker for prostate cancer diagnosis alongwith standard PSA and immunohistochemistry analysis in Pakistan. We also provide overview of animal model studies to interpret the efficacy of vitamins.
authors.affiliation: Laboratory for Translational Oncology and Personalized Medicine, RLMC, Lahore, Pakistan. ammadahmad638@yahoo.com
authors.forename: Ammad Ahmad
authors.initials: AA
authors.lastname: Farooqi
authors.forename: Ghazala
authors.initials: G
authors.lastname: Butt
authors.forename: Gohar
authors.initials: G
authors.lastname: Yousaf
authors.forename: Muhammad Imran
authors.initials: MI
authors.lastname: Qadir
authors.forename: Uzma
authors.initials: U
authors.lastname: Shaukat
authors.forename: Qaisar
authors.initials: Q
authors.lastname: Mansoor
authors.forename: Madeeha
authors.initials: M
authors.lastname: Awan
authors.forename: Shahzad
authors.initials: S
authors.lastname: Bhatti
authors.forename: Almas
authors.initials: A
authors.lastname: Begum
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating; D057285:Precision Medicine; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D053221:TNF-Related Apoptosis-Inducing Ligand; D014810:Vitamin E